

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000265

International filing date: 27 January 2005 (27.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0402143.2
Filing date: 30 January 2004 (30.01.2004)

Date of receipt at the International Bureau: 02 March 2005 (02.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

15 February 2005



The
Patent
Office

1/77

02FEB04 EB69798-6 D02029
P01/7700 0.00-0402143.2 NONE

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

ARG/NM/PB60706P

2. Patent application number

(The Patent Office will fill in his part)

0402143.2

30 JAN 2004

3. Full name, address and postcode of the or of each applicant (underline all surnames)

SmithKline Beecham Corporation
One Franklin Plaza, P.O. Box 7929, Philadelphia,
Pennsylvania 19101, United States of America

Patents ADP number (*if you know it*)

5949417004

If the applicant is a corporate body, give the country/state of its incorporation

United States of America

4. Title of the invention

Novel Compounds

5. Name of your agent (*if you have one*)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

GlaxoSmithKline
Corporate Intellectual Property (CN9 25.1)
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (*if you know it*)

8072555006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (*if you know it*) the or each application number

Country	Priority application number (<i>if you know it</i>)	Date of filing (day / month / year)
---------	--	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer yes if:*

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is named as an applicant, or
 - c) any named applicant is a corporate body
- See note (d)

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	68
Claim(s)	7
Abstract	0
Drawings	0



10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)


Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11.

We request the grant of a patent on the basis of this application

Signature  Date 30-Jan-04
A R Gladwin

12. Name and daytime telephone number of person to contact in the United Kingdom

A R Gladwin 01438 762051

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.


Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- For details of the fee and ways to pay please contact the Patent Office.

NOVEL COMPOUNDS

This invention relates to novel compounds and their use as pharmaceuticals, particularly as p38 kinase inhibitors, for the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

We have now found a group of novel compounds that are inhibitors of p38 kinase. According to the invention there is provided a compound of formula (I):



(I)

wherein

A is a fused 5-membered heteroaryl ring substituted by $-(CH_2)_m$ aryl or $-(CH_2)_m$ heteroaryl wherein the aryl or heteroaryl is optionally substituted by one or more substituents independently selected from oxo, C_{1-6} alkyl, halogen, -CN, trifluoromethyl, -OR³, $-(CH_2)_nCO_2R^3$, -NR³R⁴, $-(CH_2)_nCONR^3R^4$, -NHCOR³, -SO₂NR³R⁴, -NHSO₂R³ and -S(O)_pR³, and

A is optionally further substituted by one substituent selected from -OR⁵, halogen, trifluoromethyl, -CN, -CO₂R⁵ and C_{1-6} alkyl optionally substituted by hydroxy;

R¹ is selected from methyl and chloro;

R² is selected from -NH-CO-R⁶ and -CO-NH-(CH₂)_q-R⁷;

R³ is selected from hydrogen, $-(CH_2)_rC_{3-7}$ cycloalkyl, $-(CH_2)_r$ heterocyclyl, $-(CH_2)_r$ aryl, and C_{1-6} alkyl optionally substituted by up to two substituents independently selected from -OR⁸ and -NR⁸R⁹,

R⁴ is selected from hydrogen and C_{1-6} alkyl, or

R³ and R⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

R⁵ is selected from hydrogen and C_{1-6} alkyl;

R^6 is selected from hydrogen, C_{1-6} alkyl, $-(CH_2)_q-C_{3-7}$ cycloalkyl, trifluoromethyl, $-(CH_2)_s$ heteroaryl optionally substituted by R^{11} and/or R^{12} , and $-(CH_2)_s$ phenyl optionally substituted by R^{11} and/or R^{12} ;

5 R^7 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, $-CONHR^{13}$, phenyl optionally substituted by R^{11} and/or R^{12} , and heteroaryl optionally substituted by R^{11} and/or R^{12} ;

R^8 and R^9 are each independently selected from hydrogen and C_{1-6} alkyl;

R^{10} is selected from hydrogen and methyl;

10 R^{11} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, $-(CH_2)_q-C_{3-7}$ cycloalkyl, $-CONR^{13}R^{14}$, $-NHCOR^{14}$, halogen, $-CN$, $-(CH_2)_tNR^{15}R^{16}$, trifluoromethyl, phenyl optionally substituted by one or more R^{12} groups, and heteroaryl optionally substituted by one or more R^{12} groups;

R^{12} is selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, trifluoromethyl, and $-(CH_2)_tNR^{15}R^{16}$;

15 R^{13} and R^{14} are each independently selected from hydrogen and C_{1-6} alkyl, or

R^{13} and R^{14} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and $N-R^{10}$, wherein the ring may be substituted by up to two C_{1-6} alkyl groups;

20 R^{15} is selected from hydrogen, C_{1-6} alkyl and $-(CH_2)_q-C_{3-7}$ cycloalkyl optionally substituted by C_{1-6} alkyl,

R^{16} is selected from hydrogen and C_{1-6} alkyl, or

25 R^{15} and R^{16} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and $N-R^{10}$;

X and Y are each independently selected from hydrogen, methyl and halogen;

m, n, p and q are each independently selected from 0, 1 and 2;







r and s are each independently selected from 0 and 1; and

t is selected from 0, 1, 2 and 3;





30 with the proviso that when A is substituted by $-(CH_2)_m$ heteroaryl and m is 0, the $-(CH_2)_m$ heteroaryl group is not a 5-membered heteroaryl ring optionally substituted by C_{1-2} alkyl;

or a pharmaceutically acceptable derivative thereof.

35 In one embodiment, A includes fused 5-membered heteroaryl rings containing up to two heteroatoms independently selected from oxygen, nitrogen and sulfur. In another embodiment, A includes fused 5-membered heteroaryl rings containing up to two heteroatoms independently selected from oxygen and nitrogen. In a further embodiment, A includes 5-membered heteroaryl rings containing two heteroatoms independently selected from oxygen and nitrogen, for example rings containing a nitrogen atom and one additional heteroatom selected from oxygen and nitrogen. Examples of suitable A groups
40 include fused isoxazolyl, pyrazolyl, pyrrolyl and thiazolyl rings such as those shown below:



- 5 Representative examples of A groups include fused isoxazolyl, pyrazolyl and pyrrolyl rings such as those shown below:



- 10 A representative example of a compound of formula (I) is wherein ring A is substituted by $-(CH_2)_m$ aryl or $-(CH_2)_m$ heteroaryl, located on any position on the ring.

In one embodiment, the $-(CH_2)_m$ aryl group is $-(CH_2)_m$ phenyl.

- 15 In one embodiment, the $-(CH_2)_m$ heteroaryl group is a group wherein the heteroaryl is a 5- or 6-membered heteroaryl ring containing up to two heteroatoms independently selected from oxygen, nitrogen and sulfur. Representative examples of the $-(CH_2)_m$ heteroaryl group include groups wherein the heteroaryl is a 5- or 6-membered heteroaryl ring containing up to two heteroatoms independently selected from oxygen and nitrogen, for example pyridyl, isoxazolyl or pyrimidinyl.

- 20 The $-(CH_2)_m$ aryl and $-(CH_2)_m$ heteroaryl groups are optionally substituted and the substituents may be located on any position on the aryl or heteroaryl.

- 25 In one embodiment, the aryl or heteroaryl is optionally substituted by one or two substituents independently selected from oxo, C_{1-6} alkyl, halogen, $-CN$, trifluoromethyl, $-OR^3$, $-(CH_2)_nCO_2R^3$, $-NR^3R^4$, $-(CH_2)_nCONR^3R^4$, $-NHCOR^3$, $-SO_2NR^3R^4$, $-NHSO_2R^3$ and $-S(O)_pR^3$. Representative examples of substituents for the aryl include one or two substituents independently selected from C_{1-6} alkyl, in particular methyl, halogen, $-CN$, trifluoromethyl, $-OR^3$, $-NR^3R^4$, $-(CH_2)_nCONR^3R^4$ and $-S(O)_pR^3$. Representative examples of substituents for the heteroaryl include one or two substituents independently selected from oxo and C_{1-6} alkyl, in particular methyl.

A representative example of R^1 is methyl.

A representative example of R^2 is $-\text{CO}-\text{NH}-(\text{CH}_2)_q-\text{R}^7$.

Representative examples of R^3 include hydrogen; $-(\text{CH}_2)_r-\text{C}_{3-7}\text{cycloalkyl}$, in particular $-(\text{CH}_2)_r-\text{cyclohexyl}$; $-(\text{CH}_2)_r\text{heterocyclyl}$, in particular wherein the heterocyclyl is a 5 or 6 membered heterocyclyl containing one heteroatom selected from oxygen, nitrogen and sulfur such a tetrahydrofuran or tetrahydropyran; and $\text{C}_{1-6}\text{alkyl}$, in particular $\text{C}_{1-4}\text{alkyl}$ such as methyl, ethyl, or n-propyl, optionally substituted by up to two substituents independently selected from $-\text{OR}^8$ and $-\text{NR}^8\text{R}^9$.

A representative example of R^4 is hydrogen.

Alternatively, R^3 and R^4 , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and $\text{N}-\text{R}^{10}$, in particular morpholinyl.

In one embodiment, R^5 is selected from hydrogen and $\text{C}_{1-4}\text{alkyl}$.

In one embodiment, R^6 is a $-(\text{CH}_2)_5\text{heteroaryl}$ optionally substituted by R^{11} and/or R^{12} .

Representative examples of R^7 include hydrogen; $\text{C}_{1-6}\text{alkyl}$, in particular $\text{C}_{1-4}\text{alkyl}$ such as methyl, ethyl, n-propyl, isopropyl and n-butyl; $\text{C}_{3-7}\text{cycloalkyl}$, in particular $\text{C}_{3-6}\text{cycloalkyl}$ such as cyclopropyl, cyclobutyl and cyclopentyl; phenyl optionally substituted by R^{11} and/or R^{12} ; and heteroaryl, in particular a 5- or 6-membered heteroaryl containing two heteroatoms selected from nitrogen and oxygen, for example pyrazolyl, pyridazinyl and pyrimidinyl, optionally substituted by R^{11} and/or R^{12} .

Representative examples of R^8 and R^9 include hydrogen and $\text{C}_{1-4}\text{alkyl}$, in particular hydrogen and methyl.

A representative example of R^{11} and R^{12} is halogen, in particular fluorine.

In one embodiment, R^{13} and R^{14} are each independently hydrogen or $\text{C}_{1-4}\text{alkyl}$.

In one embodiment, R^{15} and R^{16} , together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally further containing one additional oxygen atom.

In one embodiment, X and Y are each independently selected from hydrogen, chlorine and fluorine. Representative examples of X include hydrogen and fluorine. A representative example of Y is hydrogen.

In one embodiment, when A is a fused 5-membered heteroaryl ring substituted by $-(\text{CH}_2)_m\text{aryl}$ and m is 0, 1 or 2, or A is a fused 5-membered heteroaryl ring substituted by $-(\text{CH}_2)_m\text{heteroaryl}$ and m is 1 or 2, the aryl or heteroaryl is optionally substituted by one or more substituents independently selected from oxo, $\text{C}_{1-6}\text{alkyl}$, halogen, $-\text{CN}$, trifluoromethyl, $-\text{OR}^3$, $-(\text{CH}_2)_n\text{CO}_2\text{R}^3$, $-\text{NR}^3\text{R}^4$, $-(\text{CH}_2)_n\text{CONR}^3\text{R}^4$, $-\text{NHCOR}^3$, $-\text{SO}_2\text{NR}^3\text{R}^4$, $-\text{NHSO}_2\text{R}^3$ and $-\text{S}(\text{O})_p\text{R}^3$, and, when A is a fused 5-membered heteroaryl ring substituted by $-(\text{CH}_2)_m\text{heteroaryl}$ and m is 0, the heteroaryl is a 5-membered heteroaryl ring substituted by one or more substituents independently selected from oxo, $\text{C}_{3-6}\text{alkyl}$, halogen, $-\text{CN}$, trifluoromethyl, $-\text{OR}^3$, $-(\text{CH}_2)_n\text{CO}_2\text{R}^3$, $-\text{NR}^3\text{R}^4$, $-(\text{CH}_2)_n\text{CONR}^3\text{R}^4$, $-\text{NHCOR}^3$, $-\text{SO}_2\text{NR}^3\text{R}^4$, $-\text{NHSO}_2\text{R}^3$ and $-\text{S}(\text{O})_p\text{R}^3$, the heteroaryl is a 5-membered heteroaryl ring substituted by $\text{C}_{1-2}\text{alkyl}$ and one or more substituents

independently selected from oxo, C₁₋₆alkyl, halogen, -CN, trifluoromethyl, -OR³, -(CH₂)_nCO₂R³, -NR³R⁴, -(CH₂)_nCONR³R⁴, -NHCOR³, -SO₂NR³R⁴, -NHSO₂R³ and -S(O)_pR³, or the heteroaryl is a 6-membered heteroaryl ring optionally substituted by one or more substituents independently selected from oxo, C₁₋₆alkyl, halogen, -CN, trifluoromethyl, -OR³, -(CH₂)_nCO₂R³, -NR³R⁴, -(CH₂)_nCONR³R⁴, -NHCOR³, -SO₂NR³R⁴, -NHSO₂R³ and -S(O)_pR³.

Representative examples of m include 0 and 1.

A representative example of n is 1.

A representative example of p is 2.

Representative examples of q include 0 and 1.

Representative examples of r include 0 and 1.

In one embodiment, s is 0.

In one embodiment, t is 0.

It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove. It is also to be understood that the present invention encompasses compounds of formula (I) in which a particular group or parameter, for example R³, R⁴, R⁸, R⁹, R¹⁰, R¹², R¹⁵, R¹⁶, n, p, q, r or t, may occur more than once. In such compounds it will be appreciated that each group or parameter is independently selected from the values listed.

Particular compounds according to the invention include those mentioned in the Examples. Specific examples which may be mentioned include:

N-cyclopropyl-3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide;

N-cyclopropyl-3-fluoro-5-[1-(4-fluorophenyl)-1*H*-indazol-5-yl]-4-methylbenzamide;

N-cyclopropyl-3-fluoro-5-[1-(4-fluoro-2-methylphenyl)-1*H*-indazol-5-yl]-4-

methylbenzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(4-morpholinyl)phenyl]-1*H*-indazol-5-yl}benzamide;

N-ethyl-3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide;

N-(cyclopropylmethyl)-3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(methylsulfonyl)phenyl]-1*H*-indazol-5-yl}benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-(1-{4-[2-(methylamino)-2-oxoethyl]phenyl}-1*H*-indazol-5-yl)benzamide;

N-cyclopropyl-3-[1-(4-{[2-(dimethylamino)ethyl]amino}phenyl)-1*H*-indazol-5-yl]-5-fluoro-4-

methylbenzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(tetrahydro-2*H*-pyran-4-ylamino)phenyl]-1*H*-indazol-5-yl}benzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-(1-{4-[(tetrahydro-2-furanylmethyl)amino]phenyl}-1*H*-indazol-5-yl)benzamide;

N-cyclopropyl-3-(1-{4-[(2,3-dihydroxypropyl)amino]phenyl}-1*H*-indazol-5-yl)-5-fluoro-4-methylbenzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-{3-[4-(methyloxy)phenyl]-1,2-benzisoxazol-6-yl}benzamide;

N-cyclopropyl-3-fluoro-5-[3-(4-hydroxyphenyl)-1,2-benzisoxazol-6-yl]-4-methylbenzamide;

N-cyclopropyl-3-fluoro-4-methyl-5-{1-[(1-oxido-2-pyridinyl)methyl]-1*H*-indazol-5-yl}benzamide;

N-ethyl-3-[3-(4-fluorophenyl)-1*H*-indazol-6-yl]-4-methylbenzamide;

N-cyclopropyl-3-[3-(4-fluorophenyl)-1*H*-indazol-6-yl]-4-methylbenzamide;

N-ethyl-4-methyl-3-{3-[4-(methyloxy)phenyl]-1*H*-indazol-6-yl}benzamide; and

N-cyclopropyl-4-methyl-3-{3-[4-(methyloxy)phenyl]-1*H*-indazol-6-yl}benzamide;

and pharmaceutically acceptable derivatives thereof.

As used herein, the term "pharmaceutically acceptable" means a compound which is suitable for pharmaceutical use. Salts and solvates of compounds of the invention which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of the invention and their pharmaceutically acceptable salts and solvates.

As used herein, the term "pharmaceutically acceptable derivative", means any pharmaceutically acceptable salt, solvate or prodrug, e.g. ester, of a compound of the invention, which upon administration to the recipient is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof. Such derivatives are recognizable to those skilled in the art, without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives. Preferred pharmaceutically acceptable derivatives are salts, solvates, esters, carbamates and phosphate esters. Particularly preferred pharmaceutically acceptable derivatives are salts, solvates and esters. Most preferred pharmaceutically acceptable derivatives are salts and esters, in particular salts.

The compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt. For a review on suitable salts see Berge *et al.*, J. Pharm. Sci., 1977, 66, 1-19.

Typically, a pharmaceutical acceptable salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

Salts of the compounds of the present invention may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I). Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Suitable addition salts are formed from acids which form non-toxic salts and examples are acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide,

groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of formula (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like. Esters may be active in their own right and /or be hydrolysable under *in vivo* conditions in the human body. Suitable pharmaceutically acceptable *in vivo* hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.

As used herein, the term "alkyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example, C₁₋₆alkyl means a straight or branched alkyl containing at least 1, and at most 6, carbon atoms. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl and t-butyl. A C₁₋₄alkyl group is preferred, for example methyl, ethyl, isopropyl or t-butyl. The said alkyl groups may be optionally substituted with one or more fluorine atoms for example, trifluoromethyl.

As used herein, the term "alkoxy" refers to a straight or branched chain alkoxy groups containing the specified number of carbon atoms. For example, C₁₋₆alkoxy means a straight or branched alkoxy containing at least 1, and at most 6, carbon atoms. Examples of "alkoxy" as used herein include, but are not limited to methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy, or hexyloxy. A C₁₋₄alkoxy group is preferred, for example methoxy or ethoxy.

As used herein, the term "cycloalkyl" refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms which may optionally contain up to one double bond. For example, C₃₋₇cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms. Examples of "cycloalkyl" as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A C₃₋₆cycloalkyl group is preferred, for example, cyclopropyl, cyclopentyl or cyclohexyl.

As used herein, the term "aryl" refers to an aromatic carbocyclic ring such as phenyl, biphenyl or naphthyl. Preferably the aryl is phenyl.

As used herein, the terms "heteroaryl ring" and "heteroaryl", unless otherwise defined, refer to a monocyclic 5- to 7-membered unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heteroaryl ring has five or six ring atoms. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl. The said ring may be optionally substituted by one or more substituents independently selected from C₁₋₆alkyl and oxy.

As used herein, the terms "heterocyclic ring" or "heterocyclyl", unless otherwise defined refer to a monocyclic 3- to 7-membered saturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heterocyclyl ring has five or six ring atoms. Examples of heterocyclyl groups include, but are not limited to, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidyl,

piperaziny, morpholino, tetrahydropyrany, tetrahydrofurany, and thiomorpholino. The said ring may be optionally substituted by one or more substituents independently selected from C₁₋₆alkyl and oxy.

5 As used herein, the terms "halogen" or "halo" refer to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. A particularly preferred halogen is fluorine or chlorine.

As used herein, the terms "halogen" or "halo" refer to the elements fluorine, chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. A particularly preferred halogen is fluorine or chlorine.

10 As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.

As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless
15 otherwise stated.


Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the
20 individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.

Separation of diastereoisomers or cis and trans isomers may be achieved by
25 conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. A stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active
30 acid or base, as appropriate.

Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention.


The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously
35 defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.

A compound of formula (I) may be prepared by reacting a compound of formula (II)




(II)

in which R¹, R², X and Y are as hereinbefore defined and A¹ is an unsubstituted fused 5-membered heteroaryl ring, with a suitable reagent, for example a halide derivative of
 5 formula (IIIA) or (IIIB)




(IIIA)



(IIIB)

in which $-(\text{CH}_2)_m\text{aryl}$ and $-(\text{CH}_2)_m\text{heteroaryl}$ are as hereinbefore defined and Z is halogen, in particular bromine,
 15 in, for example, the presence of a base such as sodium hydride and a solvent such as DMF.


Alternatively, when A is substituted by $-(\text{CH}_2)_m\text{aryl}$ wherein m is 0, the compound of formula (II) may be reacted with a boronic acid compound of formula (IV)



(IV)


in which $-(\text{CH}_2)_m\text{aryl}$ is as hereinbefore defined,
 in the presence of copper (I) acetate and pyridine.

A compound of formula (I) or a compound of formula (II) may be prepared by
 25 reacting a compound of formula (V)




(V)

- in which A^2 is A as hereinbefore defined, in which case the resulting product is a compound of formula (I), A^2 is A^1 as hereinbefore defined, in which case the resulting product is a compound of formula (II), or A^2 is a protected form of A or A^1 , and Z^1 is halogen, in particular bromine,
- 5 with a compound of formula (VIA) or (VIB)



(VIA)


10



(VIB)


- in which R^1 , R^2 , X and Y are as hereinbefore defined,
- in the presence of a catalyst, for example tetrakis(triphenylphosphine)palladium,
- 15 and, if necessary, removing any protecting groups.

A compound of formula (V) wherein A^2 is A and A is a fused pyrazolyl ring may, for example, be prepared by reacting a compound of formula (VII)




(VII)

- 20 in which Z^1 is as hereinbefore defined and Z^2 is halogen, in particular fluorine,
- with a hydrazine derivative of formula (VIII A) or (VIII B)




(VIII A)



(VIII B)

- 5 in which $-(\text{CH}_2)_m\text{aryl}$ and $-(\text{CH}_2)_m\text{heteroaryl}$ are as hereinbefore defined, followed by cyclisation in the presence of a base such as DBU.

Alternatively, a compound of formula (V) wherein A^2 is A and A is a fused pyrazolyl ring may, for example, be prepared by reacting a compound of formula (IX)



(IX)

10 in which Z^1 , Z^2 , $-(\text{CH}_2)_m\text{aryl}$ and $-(\text{CH}_2)_m\text{heteroaryl}$ are as hereinbefore defined, with a protected hydrazine derivative of formula (X)




(X)

in which P is a protecting group such as Boc, followed by cyclisation in the presence of a base such as DBU.

- 20 A compound of formula (V) wherein A^2 is A and A is a fused isoxazolyl ring may, for example, be prepared by reacting a compound of formula (IX) as hereinbefore defined with hydroxylamine, followed by cyclisation in the presence of a base such as DBU.

A compound of formula (VIA) may be prepared by, for example, reacting a compound of formula (XI)




(XI)

25 in which R^1 , R^2 , X and Y are as hereinbefore defined and Z^3 is halogen, in particular iodine,

with bis(pinnacolato)diboron, [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (II) complex ($\text{PdCl}_2(\text{ppdf})$) and potassium acetate in a solvent such as DMF.

- 30 A compound of formula (VIB) may be prepared by, for example, reacting a compound of formula (XI) as hereinbefore defined, with n-butyl lithium and triisopropyl borate in a solvent such as THF.

When R^2 is $-NH-CO-R^6$, a compound of formula (XI) may be prepared by reacting an amine of formula (XII)



5 (XII)

in which R^1 , X, Y and Z^3 are as hereinbefore defined, with an acid compound of formula (XIII)




10 (XIII)

in which R^6 is as hereinbefore defined, under amide forming conditions.

15 Suitable amide forming conditions are well known in the art and include adding a base such as DIPEA to a mixture of the amine of formula (XII), the acid of formula (XIII), and HATU in a solvent such as DMF.


Alternatively, when R^2 is $-CO-NH-(CH_2)_q-R^7$, a compound of formula (XI) may readily be prepared from a corresponding acid compound of formula (XIV)



20 (XIV)

in which R^1 , X, Y and Z^3 are as hereinbefore defined, by converting the acid to an activated form of the acid, for example the acid chloride, by treatment with, for example, thionyl chloride, and then reacting the activated acid thus formed with an amine compound of formula (XV)


25 (XV)



in which R^7 is as hereinbefore defined, under amide forming conditions.

30 Suitable amide forming conditions are well known in the art and include treating a solution of the acid of formula (XIV), or the activated form thereof, in for example DMF, with an amine of formula (XV) in the presence of a base such as triethylamine.


Alternatively, when R^2 is $-\text{CO}-\text{NH}-(\text{CH}_2)_q-\text{R}^7$, a compound of formula (I) may be prepared from a corresponding acid compound of formula (XVI)



(XVI)

in which A, R^1 , X and Y are as hereinbefore defined, by reacting the acid with an amine compound of formula (XV) as hereinbefore defined under the conditions described above.

When A is a fused pyrazolyl, another general method for preparing compounds of formula (I) comprises reacting a compound of formula (XVII)




(XVII)

in which R^1 , R^2 , X, Y and Z^3 are as hereinbefore defined, with a hydrazine derivative of formula (VIII A) or (VIII B) as hereinbefore defined.

Alternatively, a further general method comprises final stage modification of one compound of formula (I) into another compound of formula (I). Suitable functional group transformations for converting one compound of formula (I) into another compound of formula (I) are well known in the art and are described in, for instance, *Comprehensive Heterocyclic Chemistry II*, eds. A. R. Katritzky, C. W. Rees and E. F. V. Scriven (Pergamon Press, 1996), *Comprehensive Organic Functional Group Transformations*, eds. A.R. Katritzky, O. Meth-Cohn and C.W. Rees (Elsevier Science Ltd., Oxford, 1995), *Comprehensive Organic Chemistry*, eds. D. Barton and W.D. Ollis (Pergamon Press, Oxford, 1979), and *Comprehensive Organic Transformations*, R.C. Larock (VCH Publishers Inc., New York, 1989).


For example, one general method for preparing the compounds of formula (I) comprises the reaction set out in Scheme 1 below.



Scheme 1

5


For example, another general method for preparing the compounds of formula (I) comprises the reactions set out in Scheme 2 below.



Scheme 2


10

For example, another method for preparing the compounds of formula (I) comprises the reactions set out in Scheme 3 below.



Scheme 4

For example, a further method for preparing the compounds of formula (I) comprises the reactions set out in Scheme 5 below.



Scheme 5

Those skilled in the art will appreciate that in the preparation of the compounds of the invention it may be necessary and/or desirable to protect one or more sensitive groups in the molecule to prevent undesirable side reactions. Suitable protecting groups for use according to the present invention are well known to those skilled in the art and may be used in a conventional manner. See, for example, "Protective groups in organic synthesis" by T.W. Greene and P.G.M. Wuts (John Wiley & sons 1991) or "Protecting Groups" by P.J. Kocienski (Georg Thieme Verlag 1994). Examples of suitable amino protecting groups include acyl type protecting groups (e.g. formyl, trifluoroacetyl, acetyl), aromatic urethane type protecting groups (e.g. benzyloxycarbonyl (Cbz) and substituted Cbz), aliphatic urethane protecting groups (e.g. 9-fluorenylmethoxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), isopropyloxycarbonyl, cyclohexyloxycarbonyl) and alkyl type protecting groups (e.g. benzyl, trityl, chlorotriyl). Examples of suitable oxygen protecting groups may include for example alkyl silyl groups, such as trimethylsilyl or tert-butyldimethylsilyl; alkyl ethers such as tetrahydropyranyl or tert-butyl; or esters such as acetate.

Whilst it is possible for the compounds of the present invention to be administered as the raw chemical, the compounds of formula (I) and their pharmaceutically acceptable derivatives are conveniently administered in the form of pharmaceutical compositions eg

when the agent is in admixture with a suitable pharmaceutical excipient, diluent and/or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

Thus, in another aspect of the invention, we provide a pharmaceutical composition comprising at least one compound of formula (I) or a pharmaceutically acceptable derivative thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers. The excipient, diluent or carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

According to a further aspect, the invention provides a pharmaceutical composition comprising, as active ingredient, at least one compound of the invention or a pharmaceutically acceptable derivative thereof, in association one or more pharmaceutically acceptable excipients, diluents and/or carriers for use in therapy, and in particular in the treatment of human or animal subjects suffering from a condition susceptible to amelioration by an inhibitor of p38 kinase.

The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the compounds of the present invention and a pharmaceutically acceptable excipient, diluent and/or carrier (including combinations thereof).

There is further provided by the present invention a process of preparing a pharmaceutical composition, which process comprises mixing at least one compound of the invention or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable excipient, diluent and/or carrier.

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable excipient, diluent or carrier. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical excipient, diluent or carrier can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as – or in addition to – the excipient, diluent or carrier any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s) and solubilising agent(s).

Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

For some embodiments, the agents of the present invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and

administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e. g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO 91/11172, WO 94/02518 and WO 98/55148.

5 The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention may be prepared by processes known in the art, for example see WO 02/00196 (SmithKline Beecham).

10 There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by,
15 for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes.

20 Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit through the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

25 Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either
30 alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the
35 solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

40 The routes for administration (delivery) include, but are not limited to, one or more of: oral (e. g. as a tablet, capsule, or as an ingestible solution), topical, mucosal (e. g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e. g. by an injectable form), gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, epidural and sublingual. It is to be understood that not all of the compounds need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.

The compounds of formula (I) and their pharmaceutically acceptable salts and solvates may be formulated for administration in any suitable manner. They may, for example, be formulated for topical administration or administration by inhalation or, more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable derivatives. In a preferred embodiment, the agents of the present invention are delivered systemically such as orally, buccally or sublingually. A particularly preferred method of administration, and corresponding formulation, is oral administration.

For oral administration, the pharmaceutical composition may take the form of, and be administered as, for example, tablets (including sub-lingual tablets) and capsules (each including timed release and sustained release formulations), ovules, pills, powders, granules, elixirs, tinctures, emulsions, solutions, syrups or suspensions prepared by conventional means with acceptable excipients for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. The tablets may also contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the agent may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

Capsules can be made by preparing a powder mixture as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginite, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or saccharin, and the like can also be added.

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The compounds of the present invention can also be administered in the form of liposome emulsion delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

5 Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with
10 palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or
15 amphipathic block copolymers of hydrogels.

The present invention includes pharmaceutical compositions containing 0.1 to 99.5%, more particularly, 0.5 to 90% of a compound of the formula (I) in combination with a pharmaceutically acceptable carrier.

20 Likewise, the composition may also be administered in nasal, ophthalmic, otic, rectal, topical, intravenous (both bolus and infusion), intraperitoneal, intraarticular, subcutaneous or intramuscular, inhalation or insufflation form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

25 If the compound of the present invention is administered parenterally, then examples of such administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques. For parenteral administration, the pharmaceutical composition may
30 be given as an injection or a continuous infusion (e.g. intravenously, intravascularly or subcutaneously). The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably
35 with an added preservative. Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH
40 of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

The compositions of the present invention may be administered by direct injection.

The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

For application topically to the skin, the agent of the present invention can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.

Alternatively, it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane such as tetrafluoroethane or heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

Alternatively, the compound of the present invention can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.

The compounds of the present invention may also be administered by the pulmonary or rectal routes. They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile

saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in humans is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 µg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, dose is from about 100 µg/kg to about 5 mg/kg body weight, daily. For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.1 mg/kg to 10 mg/kg and typically around 1 mg/kg. It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the activity of the specific compound to be employed, the metabolic stability and length of action of that compound, age, weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, severity of the particular condition and response of the particular individual. The effectiveness of a selected actual dose can readily be determined, for example, by measuring clinical symptoms or standard anti-inflammatory indicia after administration of the selected dose. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. For conditions or disease states as are treated by the present invention, maintaining consistent daily levels in a subject over an extended period of time, e.g., in a maintenance regime, can be particularly beneficial. For oral and parenteral administration to humans, the daily dosage level of the agent may be in single or divided doses.

In another aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative thereof, for use in therapy.

The compounds of the present invention are generally inhibitors of the serine/threonine kinase p38 and are therefore also inhibitors of cytokine production which is mediated by p38 kinase. Within the meaning of the term "inhibitors of the serine/threonine kinase p38" are included those compounds that interfere with the ability of p38 to transfer a phosphate group from ATP to a protein substrate according to the assay described below.

It will be appreciated that the compounds of the invention may be selective for one or more of the isoforms of p38, for example p38 α , p38 β , p38 γ and/or p38 δ . In one embodiment, the compounds of the invention selectively inhibit the p38 α isoform. In another embodiment, the compounds of the invention selectively inhibit the p38 β isoform. In a further embodiment, the compounds of the invention selectively inhibit the p38 α and p38 β isoforms. Assays for determining the selectivity of compounds for the p38 isoforms are described in, for example, WO 99/61426, WO 00/71535 and WO 02/46158.

It is known that p38 kinase activity can be elevated (locally or throughout the body), p38 kinase can be incorrectly temporally active or expressed, p38 kinase can be expressed or active in an inappropriate location, p38 kinase can be constitutively expressed, or p38 kinase expression can be erratic; similarly, cytokine production mediated by p38 kinase activity can be occurring at inappropriate times, inappropriate locations, or it can occur at detrimentally high levels.

Accordingly, the present invention provides a method for the treatment of a condition or disease state mediated by p38 kinase activity, or mediated by cytokines produced by the activity of p38 kinase, in a subject which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.

The present invention also provides a method of inhibiting cytokine production which is mediated by p38 kinase activity in a subject, e.g. a human, which comprises administering to said subject in need of cytokine production inhibition a therapeutic, or cytokine-inhibiting, amount of a compound of the present invention. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.

The present invention treats these conditions by providing a therapeutically effective amount of a compound of this invention. By "therapeutically effective amount" is meant a symptom-alleviating or symptom-reducing amount, a cytokine-reducing amount, a cytokine-inhibiting amount, a kinase-regulating amount and/or a kinase-inhibiting amount of a compound. Such amounts can be readily determined by standard methods, such as by measuring cytokine levels or observing alleviation of clinical symptoms. For example, the clinician can monitor accepted measurement scores for anti-inflammatory treatments. It will be appreciated that reference to treatment includes acute treatment or prophylaxis as well as the alleviation of established symptoms.

The compounds of the present invention can be administered to any subject in need of inhibition or regulation of p38 kinase or in need of inhibition or regulation of p38 mediated cytokine production. In particular, the compounds may be administered to mammals. Such mammals can include, for example, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.

Thus, the present invention provides methods of treating or reducing symptoms in a human or animal subject suffering from, for example, rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease,

Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs. host reaction, allograft rejections, sepsis, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), malaria, leprosy, infectious arthritis, leishmaniasis, Lyme disease, glomerulonephritis, gout, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, Crohn's disease, ulcerative colitis, acute synovitis, gouty arthritis, spondylitis, and non articular inflammatory conditions, for example, herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendonitis, tenosynovitis, fibromyalgic syndrome and other inflammatory conditions associated with ligamentous sprain and regional musculoskeletal strain, pain, for example that associated with inflammation and/or trauma, osteopetrosis, restenosis, thrombosis, angiogenesis, cancer including breast cancer, colon cancer, lung cancer or prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, chronic pulmonary inflammation, chronic obstructive pulmonary disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia,

inflammatory neuropathies and migraine pain which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof.

5 A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for use in the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity.

10 The compounds of formula (I) and their derivatives may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions. The invention thus provides, in a further aspect, a combination comprising a compound of the invention or a pharmaceutically acceptable derivative thereof together with a further therapeutic agent.

15 In particular, in rheumatoid arthritis therapy, combination with other chemotherapeutic or antibody agents is envisaged. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent. The compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may
20 occur separately or sequentially in any order. The amounts of the compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. Appropriate doses will be readily appreciated by those skilled in the art. It will be appreciated that the amount of a
25 compound of the invention required for treatment will vary with the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or veterinarian. Examples of other pharmaceutically active agents which may be employed in combination with compounds of formula (I) and their salts and solvates for rheumatoid arthritis therapy include: immunosuppressants such as amtolmetin guacil, mizoribine and rimexolone; anti-TNF α agents such as etanercept, infliximab, diacerein; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101 (Aventis); interleukin 1 receptor antagonists such as anakinra; CD8 antagonists such as amiprilose hydrochloride; beta amyloid
30 precursor protein antagonists such as reumacon; matrix metalloprotease inhibitors such as cipemastat and other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporin A, hydroxychloroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine.

35 The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the invention.
40

The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations by any convenient route.

5 When administration is sequential, either the compound of the invention or the second therapeutic agent may be administered first. When administration is simultaneous, the combination may be administered either in the same or different pharmaceutical composition.

10 When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation. When formulated separately they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.

EXAMPLES

The following Examples are illustrative embodiments of the invention, not limiting the scope of the invention in any way. Reagents are commercially available or are prepared according to procedures in the literature.

{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid, *N*-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid may be prepared by the procedures described in WO 03/068747.

(4-Fluoro-2-methylphenyl)boronic acid may be prepared by the procedure described by J.B. Doherty, *et al.* in WO 02/058695.

5-Bromoindazole may be prepared by the procedure described by A. Arnautu *et al.* in Tetrahedron Letters, 2002, 43, 2695.

3-(Bromomethyl)-5-methylisoxazole and 4-hydrazino-2,6-dimethylpyrimidine may be purchased from Maybridge International.

[4-(4-Morpholinyl)phenyl]boronic acid may be purchased from AsymChem International.

5-Bromo-1-(2-pyridinyl)-1*H*-indole, 5-bromo-1-(3-pyridinyl)-1*H*-indole and 3-(5-bromo-1*H*-indol-1-yl)benzonitrile may be prepared by the procedures described by G.H. Ladouceur, *et al.* in WO 03/027094.

4-Methylsulfonylphenylhydrazine may be purchased from Apin Chemical Ltd.

2-(4-Aminophenyl)-*N*-methylacetamide may be prepared by the procedure described by J.A. Cipollina, *et al.* in EP 666 258 A1.

Tetrahydro-2*H*-pyran-4-ylamine may be prepared by the procedure described by M Allegretti, *et al.* in Tetrahedron Letters, 2001, 42, 57.

6-Hydrazino-4(1*H*)-pyrimidinone may be prepared by the procedure described by B.E. Christensen, *et al.* in Journal of Organic Chemistry, 1971, 36, 2462.


6-Bromo-3-[4-(methyloxy)phenyl]-1,2-benzisoxazole and 4-(6-bromo-1,2-benzisoxazol-3-yl)phenol may be prepared by the procedures described by J. Aebi, *et al.* in EP 778 271 A2.

2-Aminopyridazine may be purchased from Sigma-RBI.

(4-Bromo-2-fluorophenyl)(4-fluorophenyl)methanone and (4-bromo-2-fluorophenyl)[4-(methyloxy)phenyl]methanone may be prepared by the procedures described by A Levy *et al.* in Journal of Organic Chemistry, 2003, 68, 3990.


LCMS was conducted on a column (3.3cm x 4.6mm ID, 3µm ABZ+PLUS), at a Flow Rate of 3ml/min, Injection Volume of 5µl, at room temperature and UV Detection Range at 215 to 330nm.

Intermediate 1: 5-Bromo-1-phenyl-1*H*-indazole




A solution of 5-bromo-2-fluorobenzaldehyde (10.0g) in boiling acetonitrile (90ml) was added to a solution of phenylhydrazine (8.3g) in boiling acetonitrile (360ml). The yellow solution was stirred for 5min, allowed to cool then concentrated under vacuum. The resulting solid was washed with hexane (3x10ml) and the residue was dissolved in DMSO (125ml). Cesium carbonate (32.9g) was added and the mixture was heated at 140°C for 24h then at 150°C for 40h. The reaction mixture was diluted with ethyl acetate (600ml) then washed with saturated sodium hydrogen carbonate (2x300ml) and brine (2x300ml). The solvent was removed under vacuum and the residue was recrystallised from methanol to give the title compound as a white solid (6.98g).
LC-MS: Rt 3.19min, MH⁺ 273/275.

Intermediate 2: 5-Bromo-1-(4-fluorophenyl)-1H-indazole




A solution of 4-fluorophenylhydrazine hydrochloride (27.4g) in ethyl acetate (50ml), was washed with saturated sodium hydrogen carbonate (3x20ml), dried and concentrated under vacuum. The resulting oil was dissolved in boiling acetonitrile (36ml) and a solution of 5-bromo-2-fluorobenzaldehyde (20g) in boiling acetonitrile (9ml) was added. The solution was allowed to cool, the solvent was evaporated and the residue was dissolved in DMSO (200ml). Cesium carbonate added and the mixture was heated by microwave in a sealed vessel at 200°C for 10min. The reaction mixture was diluted with ethyl acetate (1000ml) then washed with hydrochloric acid (1M, 3 x 200ml), saturated sodium hydrogen carbonate (2 x 200ml) and brine (200ml). The organic phase was dried and concentrated under vacuum and the residue was recrystallised from hexane to give the title compound as a white crystalline solid (16.98g).
LC-MS: Rt 3.13min, MH⁺ 291/293.

Intermediate 3: tert-Butyl 5-bromo-1H-indazole-1-carboxylate



- 5 A stirred ice-cold suspension of 5-bromoindazole (2g), 4-(dimethylamino)pyridine (250mg) and triethylamine (1.55ml) in acetonitrile (50ml) was treated with a solution of di-tert-butyl dicarbonate (2.8ml) in acetonitrile (20ml) over 15 min such that the temperature remained under 5°C. The reaction mixture was warmed to room temperature then stirred for 18h. The solvent was evaporated and the residue was purified by column chromatography on silica (100g) eluting with cyclohexane:ethyl acetate (15:1) to give the title compound (2.27g).
- 10 LCMS: Rt 3.55min.


Intermediate 4: 1,1-Dimethylethyl 5-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1H-indazole-1-carboxylate



15

- 20 A mixture of tert-butyl 5-bromo-1H-indazole-1-carboxylate (Intermediate 3, 1.07g), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (0.85g), sodium carbonate (1.9g) and tetrakis(triphenylphosphine)palladium(0) (0.42g) in 1,2-dimethoxyethane (70ml) was stirred at reflux under nitrogen for 20h. The solvent was removed and the residue was partitioned between water (50ml) and ethyl acetate (50ml). The aqueous layer was re-extracted with ethyl acetate (3x30ml) and the combined organic extracts were dried using a hydrophobic filter tube and concentrated under vacuum.
- 25 The residue was purified by column chromatography on silica eluting with cyclohexane:ethyl acetate (75:25 to 60:40) to give the title compound (3.1g).
LCMS: Rt 3.46min, MH+ 410.


Intermediate 5: N-Cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide



A mixture of 1,1-dimethylethyl 5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl-1H-indazole-1-carboxylate (Intermediate 4, 0.46g) in a solution of hydrogen chloride in dioxan (4M, 7ml) was stirred at room temperature under nitrogen for 4.5h. The solvent was evaporated and the residue was partitioned between dichloromethane (20ml) and aqueous sodium hydroxide (2M, 20ml). The organic layer was separated using a hydrophobic filter tube, the solvent was evaporated and the residue was purified on a Varian Bond-Elut SPE cartridge (silica, 10g) eluting with chloroform:methanol (100:0 to 98:2) to give the title compound (0.06g).

LCMS: Rt 2.96min, MH⁺ 310.


Intermediate 6: (N-Cyclobutyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide



A mixture of 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (262mg) in chloroform (10ml) was stirred with 3-[(ethylimino)methylidene]amino}-N,N,N-trimethyl-1-propanaminium iodide (450mg), 1-hydroxy-7-azabenzotriazole (13mg) and cyclobutylamine (102μl) for 18h. Water was added, the organic layer was separated using a hydrophobic filter tube and the solvent was removed under vacuum to give the title compound (210mg).


NMR: [δH d₆-DMSO] 8.59 (1H d, J=8Hz), 8.08 (1H, d, J=1Hz), 7.81 (1H, dd, 8Hz J=1Hz), 7.26 (1H, d, J=8Hz), 4.47-4.37 (1H, m), 2.50 (3H, s), 2.25-2.15 (2H, m), 2.14-2.03 (2H, m), 1.70-1.62 (2H, m), 1.32 (12H, s).

Intermediate 7: Methyl 3-fluoro-5-iodo-4-methylbenzoate




- A stirred mixture of 3-fluoro-4-methylbenzoic acid (10.3g) in trifluoromethane sulfonic acid (50ml) at -20°C was treated with N-iodosuccinimide in portions over 40min. The reaction was stirred at -10°C for 44h when a further amount of N-iodosuccinimide (6.0g) was added. After 20h the reaction mixture was added to ice/water and extracted with ethyl acetate. The organic solution was washed with aqueous sodium metabisulfite and dried over sodium sulfate. The residue was dissolved in methanol (50ml), the solution was treated with concentrated sulfuric acid (91ml) and the mixture was heated at reflux for 6h. The solvent was evaporated and the residue was dissolved in ethyl acetate. This solution was washed with aqueous sodium bicarbonate and dried with brine and over magnesium sulfate. Purification by biotage chromatography (x2), firstly using cyclohexane/ethyl acetate (100/1) and secondly cyclohexane/toluene (6/1) as eluents gave the title compound (9.31g). LC-MS: Rt 3.55min.

Intermediate 8: Methyl 3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate



- A mixture of methyl 3-fluoro-5-iodo-4-methylbenzoate (Intermediate 7, 9.04g), potassium acetate (15.06g), bis(pinacolato)diborane (11.7g) and [1,1'-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (251mg) in DMF (200ml) was deoxygenated then stirred at 90°C for 18h. The reaction mixture was evaporated to dryness, pre-absorbed on to silica and purified by Biotage chromatography using a cyclohexane/ethyl acetate gradient as eluent to give the title compound (8.39g). LC-MS: Rt 3.78min.


Intermediate 9: 3-Fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)benzoic acid



5 A mixture of 5-bromo-1-phenyl-1*H*-indazole (Intermediate 1, 272mg), methyl 3-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (Intermediate 8, 294mg), tetrakis(triphenylphosphine)palladium (0) (30mg) and 1M aqueous sodium bicarbonate (10ml) in isopropanol (10ml) was heated at reflux for 3h. The reaction mixture was acidified with 2M hydrochloric acid then diluted with ethyl acetate. The organic layer was separated using a hydrophobic filter tube, the solvent was evaporated and the residue was purified on an SPE cartridge (silica) eluting with a petroleum ether/ethyl acetate gradient containing 0.1% acetic acid to give the title compound as a colourless solid (227mg).

10 LC-MS: Rt 3.94min MH⁺ 347.

Intermediate 10: 4-(5-Bromo-1*H*-indol-1-yl)benzonitrile




15

A solution of 5-bromo-1*H*-indole (196mg) and sodium hydride (60% dispersion in mineral oil, 24mg) in DMF (6ml) was stirred at room temperature under nitrogen for 1h. A solution of 4-fluorobenzonitrile (446mg) in DMF (0.5) was added and the resulting mixture was stirred at 100°C under nitrogen for 12h. The mixture was partitioned between water and ethyl acetate and the organic layer was washed with water and brine, dried through a hydrophobic filter tube and concentrated under vacuum. The residue was partially purified on an SPE cartridge (silica, 5g) eluting with cyclohexane:ethyl acetate (99:1 to 1:1) to give impure title compound as a yellow oil.


25 LC-MS: Rt 3.27.

Intermediate 11: 5-Bromo-1-(3-methylphenyl)-1*H*-indazole



- A mixture of 3-methylphenylhydrazine (240mg) and 5-bromo-2-fluorobenzaldehyde (0.2ml) in acetonitrile (1ml) was stirred at room temperature for 1h. The solvent was removed under vacuum and the residue was dissolved in DMSO (2ml).
 5 Cesium carbonate (510mg) was added and the mixture was heated in a microwave oven at 200°C for 10min. The reaction mixture was diluted with ethyl acetate (10ml) then washed with hydrochloric acid (1M), aqueous sodium hydrogen carbonate and brine. The solvent was removed under vacuum and the residue was purified using an SPE cartridge (silica), eluting with cyclohexane to give the title compound as a yellow oil (157mg).
 10 LC-MS: Rt 3.81min, MH⁺ 287, 289.


Intermediate 12: 5-Bromo-1-[4-(trifluoromethyl)phenyl]-1H-indazole



15

- The procedure for Intermediate 11 was followed using 4-trifluoromethylphenylhydrazine (300mg), 5-bromo-2-fluorobenzaldehyde (0.2ml), acetonitrile (1ml), DMSO (2ml) and cesium carbonate (580mg) to give the title compound
 20 (202mg).
 LC-MS: Rt 3.90min.


Intermediate 13: 5-Bromo-1-[4-(methylsulfonyl)phenyl]-1H-indazole



The procedure for Intermediate 11 was followed using 4-methylsulfonylphenylhydrazine (333mg), 5-bromo-2-fluorobenzaldehyde (0.21ml),
 5 acetonitrile (1ml), DMSO (2ml) and cesium carbonate (650mg) to give the title compound as a yellow solid (470mg).

LC-MS: Rt 3.24min, MH⁺ 351, 353.

Intermediate 14: 2-(4-Hydrazinophenyl)-N-methylacetamide, hydrochloride




Sodium nitrite (8.5g) in water (18ml) was added over 30min to a stirred solution of 2-(4-aminophenyl)-N-methylacetamide (20g) in concentrated hydrochloric acid (41ml) at
 15 -7°C. The reaction mixture was stirred for 1h at -5°C then added over 30min to a solution of tin (II) chloride dihydrate (136.5g) in concentrated hydrochloric acid (160ml) maintaining a temperature below 0°C throughout. The reaction was stirred at -5°C for 2h and the white precipitate was collected by filtration and washed with ether (2x30ml). The solid was dissolved in hot methanol (110ml), filtered through Hyflo™ then treated with hot
 20 isopropyl acetate (325ml). The solution was allowed to cool, chilled in an ice bath and the resulting precipitate was collected by filtration, washed with isopropyl acetate (2x25ml) and dried to give the title compound as a white solid (22.2g).

Microanalysis: Found: C 49.09, H 6.53, N 18.92.

Calculated for C₉H₁₃N₃O.HCl. 0.25H₂O: C 49.09, H 6.64, N 19.08.


Intermediate 15: 2-[4-(5-Bromo-1H-indazol-1-yl)phenyl]-N-methylacetamide



The procedure for Intermediate 11 was followed using 2-(4-hydrazinophenyl)-N-methylacetamide (Intermediate 14, 333mg), 5-bromo-2-fluorobenzaldehyde (0.21ml), acetonitrile (1ml), DMSO (2ml) and cesium carbonate (650mg) to give the title compound as a brown solid (495mg).

LC-MS: Rt 3.09min, MH+ 344, 346.


Intermediate 16: *N*-Cyclopropyl-4',5-difluoro-3'-formyl-6-methyl-3-biphenylcarboxamide



5-Bromo-2-fluorobenzaldehyde (0.48ml), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (1.1g), tetrakis(triphenylphosphine) palladium (101mg) and aqueous sodium hydrogen carbonate (1M, 8ml) were combined in isopropanol (16ml) and heated at 85°C for 18h. The cooled mixture was absorbed onto silica and applied to an SPE cartridge (silica, 50g). Elution with cyclohexane/ethyl acetate (4:1 to 1:1) gave the title compound as a yellow oil (650mg).


LC-MS: Rt 3.09min, MH+ 316.

Intermediate 17: *N*-(4-Fluorophenyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide




The procedure for Intermediate 6 was followed using 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (655mg), 3-[[[(ethylimino)methylidene]amino]-N,N,N-trimethyl-1-propanaminium iodide (719mg), 1-hydroxy-7-azabenzotriazole (34mg) and 4-fluoroaniline (360µl) in chloroform (10ml). The crude product, in methanol (30ml) was applied to an SCX cartridge and eluted with methanol to give the title compound as a pink foam (780mg).
LC-MS: Rt 3.62min.

Intermediate 18: N-Ethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide



The procedure for Intermediate 6 was followed using 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (1.31g), 3-[[[(ethylimino)methylidene]amino]-N,N,N-trimethyl-1-propanaminium iodide (2.23g), 1-hydroxy-7-azabenzotriazole (68mg) and a solution of ethylamine in THF (2M, 5ml) in chloroform (30ml). The crude product, in methanol was applied to an SCX cartridge and eluted with methanol to give the title compound as a pale yellow solid (1.36g).
LC-MS: Rt 3.20min.


Intermediate 19: 1,1-Dimethylethyl (2Z)-2-[(4-bromo-2-fluorophenyl)(4-fluorophenyl)methylidene]hydrazinecarboxylate



A mixture of (4-bromo-2-fluorophenyl)(4-fluorophenyl)methanone (176mg), tert-butyl carbazate (76mg) and acetic acid in methanol (4ml) was stirred at reflux for 66h. The reaction mixture was partitioned between water and ethyl acetate, the phases were separated and the organic layer was washed with water and brine. The dried (Na_2SO_4) extracts were concentrated under vacuum and the residue was purified on a SPE cartridge (silica, 5g) eluting with cyclohexane/ethyl acetate (9:1) to give the title compound as a white solid (141mg).

LC-MS: Rt 3.71min.


Intermediate 20: 6-Bromo-3-(4-fluorophenyl)-1H-indazole



A solution of 1,1-dimethylethyl (2Z)-2-[(4-bromo-2-fluorophenyl)(4-fluorophenyl)methylidene]hydrazinecarboxylate (Intermediate 19, 141mg) and 1,8-diazabicyclo[5.4.0]undec-7-ene (32 μ l) in THF (5ml) was heated at 150°C for 30min in a microwave oven. Water and chloroform were added and the organic layer was separated using a hydrophobic filter tube. The solvent was evaporated and the residue was purified on an SPE cartridge (silica, 2g) eluting with cyclohexane/ethyl acetate (100:0 to 80:20) to give the title compound (42mg).


LC-MS: Rt 3.71min.

Intermediate 21: 1,1-Dimethylethyl 2-[(4-bromo-2-fluorophenyl)[4-(methoxy)phenyl]methylidene}



The procedure for Intermediate 19 was followed using (4-bromo-2-fluorophenyl)[4-(methoxy)phenyl]methanone (183mg) tert-butyl carbazate (76mg) acetic acid (0.4ml) and methanol (4ml) to give the title compound as a yellow solid (110mg).
LC-MS: Rt 3.62min.

Intermediate 22: 6-Bromo-3-[4-(methoxy)phenyl]-1H-indazole




10

The procedure for Intermediate 20 was followed using 1,1-dimethylethyl 2-((4-bromo-2-fluorophenyl)[4-(methoxy)phenyl]methylidene)hydrazinecarboxylate Intermediate 21, 110mg) and 1,8-diazabicyclo[5.4.0]undec-7-ene (39μl) and THF (5ml) to give the title compound (53mg).
LC-MC: Rt 3.62min.

15


Example 1: N-Cyclopropyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)benzamide



20


- 5 A mixture of 5-bromo-1-phenyl-1*H*-indazole (Intermediate 1, 34.6mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (30mg), tetrakis(triphenylphosphine) palladium (3mg) and aqueous sodium hydrogen carbonate (1M, 0.63ml) in isopropanol (2ml) in a sealed vessel was heated in a microwave oven at 150°C for 10min (70W). The reaction mixture was filtered, the solvents were removed under vacuum and the residue was purified by preparative HPLC to give the title compound (32mg).
LC-MS: Rt 3.54min, MH+ 386.

10 **Example 2: N-Cyclopropyl-3-fluoro-5-[1-(4-fluorophenyl)-1*H*-indazol-5-yl]-4-methylbenzamide**



- 15 The procedure for Example 1 was followed using 5-bromo-1-(4-fluorophenyl)-1*H*-indazole (Intermediate 2, 36.6mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (30mg), tetrakis(triphenylphosphine) palladium (3mg) and aqueous sodium hydrogen carbonate (1M, 0.63ml) in isopropanol (2ml) to give the title compound (30.7mg).
20 LC-MS: Rt 3.56min, MH+ 404.


Example 3: N-Cyclopropyl-3-fluoro-5-[1-(4-fluoro-2-methylphenyl)-1*H*-indazol-5-yl]-4-methylbenzamide



A mixture of *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 31mg), (4-fluoro-2-methylphenyl)boronic acid (31mg), anhydrous copper (II) acetate (27mg), pyridine (16.4μl) and 4Å powdered molecular sieves (75mg) in dichloromethane (2ml) was stirred at room temperature for 24h. Further dichloromethane (1ml) was added and after 24h the reaction mixture was diluted with chloroform (3ml) and water (3ml). The organic phase was separated using a hydrophobic filter tube and the solvent was evaporated. The residue was purified by preparative HPLC to give the title compound as a yellow gum (10.5mg).

LC-MS: Rt 3.63min, MH⁺ 418.


Example 4: *N*-Cyclopropyl-3-fluoro-5-{1-[(4-fluorophenyl)methyl]-1*H*-indazol-5-yl}-4-methylbenzamide



A solution of *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 31mg) and sodium hydride (60% dispersion in mineral oil, 4mg) in DMF (1.6ml) was stirred at room temperature under nitrogen. After 1 hour, 1-(bromomethyl)-4-fluorobenzene (15μl) was added and the resulting mixture was allowed to stir under nitrogen at room temperature. After 1h, ammonia (aqueous 0.88, 200μl) was added and the resulting mixture was allowed to stir under nitrogen at room temperature. After 1h, the mixture was concentrated. The residue was purified by preparative HPLC to give the title compound (7mg).

LC-MS: Rt 3.49, MH⁺ 418.


Example 5: *N*-Cyclopropyl-3-fluoro-4-methyl-5-(1-{[4-(trifluoromethyl)phenyl]methyl}-1*H*-indazol-5-yl)benzamide



The procedure for Example 4 was followed using *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 31mg), sodium hydride (60% dispersion in mineral oil, 4mg), 1-(bromomethyl)-4-(trifluoromethyl)benzene (19μl) and DMF (1.6ml) to give the title compound (6mg).

5 LC-MS: Rt 3.65, MH⁺ 468.

Example 6: *N*-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylmethyl)-1*H*-indazol-5-yl]benzamide



10


The procedure for Example 4 was followed using *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 31mg), sodium hydride (60% dispersion in mineral oil, 4mg), (bromomethyl)benzene (14μl) and DMF (1.6ml) to give the title compound (9mg).

15

LC-MS: Rt 3.48, MH⁺ 400.

Example 7: *N*-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(5-methyl-3-isoxazolyl)methyl]-1*H*-indazol-5-yl]benzamide

20




Sodium hydride (60% in mineral oil, 12mg) was added to *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 45mg) in DMF (5ml) and the mixture was stirred at room temperature for 1h. 3-(Bromomethyl)-5-methylisoxazole (28.2mg) was added and stirring was continued for 18h. The mixture was diluted with chloroform/ethyl acetate (1:1, 5ml) and washed with water (2x5ml). The organic phase was concentrated under vacuum and the residue was purified on a silica column eluting with chloroform/ethyl acetate (9:1) to give the title compound as a colourless glass (10mg).

25

30

LC-MS: Rt 3.14min, MH+ 405.

Example 8: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]benzamide




5

The procedure for Example 7 was followed using *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 45mg), sodium hydride (60% in mineral oil, 18mg), 2-(bromomethyl)pyridine (40mg) and DMF (5ml) to give the title compound as a colourless glass (10mg).

10 LC-MS: Rt 3.07min, MH+ 401.

Example 9: N-Cyclopropyl-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methylbenzamide



15


A mixture of 5-bromo-1-(4-fluorophenyl)-1*H*-indazole (Intermediate 2, 29mg), *N*-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (30mg), tetrakis(triphenylphosphine)palladium (0) (6mg) and 1M aqueous sodium bicarbonate (1ml) in 2-propanol (1 ml) was heated at 150°C for 15mins in a microwave oven. The reaction mixture was diluted with chloroform and the organic layer was separated using a hydrophobic filter tube. The organic layer was evaporated and the residue was purified on an SPE cartridge (silica) using a petroleum ether/ethyl acetate gradient to give the title compound as a colourless gum (34mg).

20

LC-MS: Rt 3.50min MH+ 386.

25

Example 10: N-Cyclobutyl-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]-4-methylbenzamide




5

A mixture of 5-bromo-1-(4-fluorophenyl)-1H-indazole (Intermediate 2, 29mg), N-cyclobutyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 6, 32mg), tetrakis(triphenylphosphine)palladium (0) (6mg) and 1M aqueous sodium bicarbonate in 2-propanol (1 ml) was heated at 150°C for 15min in a microwave oven. The reaction mixture was diluted with chloroform and the organic layer separated using a hydrophobic filter tube. The organic layer was evaporated and the residue was purified on an SPE cartridge (silica) eluting with a petroleum ether/ethyl acetate gradient to give the title compound as a colourless gum (34mg).
LC-MS: Rt 3.66min, MH⁺ 400.

10

15

Example 11: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(4-morpholinyl)phenyl]-1H-indazol-5-yl]benzamide, formate salt

HCO₂H

20

25

A mixture of N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 80mg), [4-(4-morpholinyl)phenyl]boronic acid (105mg), anhydrous copper (II) acetate (71mg), pyridine (40μl) and 4Å powdered molecular sieves (200mg) in dichloromethane (5ml) was stirred at room temperature for 24h. Further dichloromethane (1ml) was added and after 24h the reaction mixture was diluted with chloroform (3ml) and water (3ml). The organic phase was separated using a hydrophobic filter tube and the

solvent was evaporated. The residue was purified by preparative HPLC to give the title compound as an off-white solid (32mg).


LC-MS: Rt 3.42min, MH⁺ 471.

5 General Method 1

10 A mixture of 3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzoic acid (Intermediate 9, 70mg) in thionyl chloride (3ml) was stirred at reflux for 30min. Excess thionyl chloride was removed under vacuum and the residue was azeotroped with toluene to remove residual thionyl chloride. The crude acid chloride was dissolved in chloroform (3.1ml) and an aliquot (300μl) was treated with an amine (50μmol) in chloroform (1ml). After 1h the reaction mixture was diluted with chloroform and washed with 1M aqueous hydrochloric acid followed by aqueous sodium hydrogen carbonate. The organic layer was separated using a hydrophobic filter tube then concentrated under vacuum to give the title compound.

15


Example 12: 3-Fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide



The title compound (8.3mg) was prepared by General Method 1 using a solution of ammonia in dioxan (0.5M).

20 LC-MS: Rt 3.43min, MH⁺ 346.


Example 13: 3-Fluoro-*N*,4-dimethyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide



The title compound (2.0mg) was prepared by General Method 1 using a solution of methylamine in tetrahydrofuran (2M).

LC-MS: Rt 3.52min, MH+ 360.

5 **Example 14: N-Ethyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)benzamide**




The title compound (5.9mg) was prepared by General Method 1 using a solution of ethylamine in tetrahydrofuran (2M).

LC-MS: Rt 3.62min, MH+ 374.

10


Example 15: 3-Fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-propylbenzamide



15 The title compound (6.4mg) was prepared by General Method 1 using propylamine.


LC-MC: 3.73min, MH+ 388.

Example 16: N-Butyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)benzamide



The title compound (4.6mg) was prepared by General Method 1 using butylamine.
LC-MS: Rt 3.86min, MH⁺ 402.


5 **Example 17: N-Cyclobutyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)benzamide**



The title compound (6.6mg) was prepared by General Method 1 using cyclobutylamine.

10 LC-MS: Rt 3.77min, MH⁺ 400.


Example 18: N-Cyclopentyl-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)benzamide



15 The title compound (6.5mg) was prepared by General Method 1 using cyclopentylamine.

LC-MS: Rt 3.84min, MH⁺ 414.

20 **Example 19: 3-Fluoro-4-methyl-N-(1-methylethyl)-5-(1-phenyl-1H-indazol-5-yl)benzamide**




The title compound (6.6mg) was prepared by General Method 1 using isopropylamine.

LC-MS: Rt 3.68min, MH+ 387.

5

Example 20: N-(Cyclopropylmethyl)-3-fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)benzamide




The title compound (6.5mg) was prepared by General Method 1 using cyclopropylmethylamine.

LC-MS: Rt 3.67min, MH+ 400.

10

Example 21: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinyl)-1H-indol-5-yl]benzamide




A suspension of and 5-bromo-1-(2-pyridinyl)-1H-indole (27mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (26mg), tetrakis(triphenylphosphine)palladium(0) (1mg) and aqueous sodium hydrogen carbonate

15

(1M, 0.3ml) in isopropanol (0.6ml) was heated at 150°C in a microwave oven for 15min. The mixture was partitioned between water and ethyl acetate and the organic layer was washed with water and brine, dried using a hydrophobic filter tube and concentrated under vacuum. The residue was purified by preparative HPLC to give the title compound (15mg).

LC-MS: Rt 3.6, MH⁺ 386.


Example 22: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinyl)-1H-indol-5-yl]benzamide



The procedure for Example 21 was followed using 5-bromo-1-(3-pyridinyl)-1H-indole (27mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (26mg), tetrakis(triphenylphosphine)palladium (0) (1mg) and aqueous sodium hydrogen carbonate (1M, 0.3ml) in isopropanol (0.6ml) to give the title compound (18mg).


LC-MS: Rt 3.31, MH⁺ 386.

Example 23: 3-[1-(4-Cyanophenyl)-1H-indol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide



The procedure for Example 21 was followed using 4-(5-bromo-1H-indol-1-yl)benzonitrile (Intermediate 10, 30mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (26mg), tetrakis(triphenylphosphine)palladium (0) (1mg) and aqueous sodium hydrogen carbonate (1M, 0.3ml) in isopropanol (0.6ml) to give the title compound (2.7mg).


LC-MS: Rt 3.64, MH⁺ 410.

Example 24: 3-[1-(3-Cyanophenyl)-1H-indol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide

5

The procedure for Example 21 was followed using 3-(5-bromo-1H-indol-1-yl)benzonitrile (30mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (26mg), tetrakis(triphenylphosphine)palladium (0) (1mg) and aqueous sodium hydrogen carbonate (1M, 0.3ml) in isopropanol (0.6ml) to give the title compound (2.9mg). LC-MS: Rt 3.64, MH⁺ 410.

10

Example 25: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)-1H-indazol-5-yl]benzamide

15


A mixture of 5-bromo-1-(3-methylphenyl)-1H-indazole (Intermediate 11, 179mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (173mg), tetrakis(triphenylphosphine)palladium (18.7mg) and aqueous sodium hydrogen carbonate (1M, 1ml) in propan-2-ol (2.5ml) was heated in a microwave oven at 150°C for 10min. The solvent was evaporated and the residue was partitioned between chloroform and water. The organic phase was absorbed onto silica and purified on an SPE cartridge (silica) eluting with an cyclohexane/ethyl acetate gradient to give the title compound as a glass (153mg).

20

LC-MS: Rt 3.73min, MH⁺ 400.


25

Example 26: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[4-(trifluoromethyl)phenyl]-1H-indazol-5-yl]benzamide




The procedure for Example 25 was followed using 5-bromo-1-[4-(trifluoromethyl)phenyl]-1*H*-indazole (Intermediate 12, 202mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (167mg), tetrakis(triphenylphosphine)palladium (13.8mg) and aqueous sodium hydrogen carbonate (1M, 1.2ml) in isopropanol (2.8ml) to give the title compound (115mg). LC-MS: Rt 3.85min, MH⁺ 454.

10 **Example 27: N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(methylsulfonyl)phenyl]-1*H*-indazol-5-yl}benzamide**



The procedure for Example 25 was followed using 5-bromo-1-[4-(methylsulfonyl)phenyl]-1*H*-indazole (Intermediate 13, 210mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (167mg), tetrakis(triphenylphosphine)palladium (13.8mg) and aqueous sodium hydrogen carbonate (1M, 1.2ml) in isopropanol (2.8ml) to give the title compound as a pale yellow foam (156mg). LC-MS: Rt 3.28min, MH⁺ 464.


20 **Example 28: N-Cyclopropyl-3-fluoro-4-methyl-5-(1-{4-[2-(methylamino)-2-oxoethyl]phenyl}-1*H*-indazol-5-yl)benzamide**



The procedure for Example 25 was followed using 2-[4-(5-bromo-1*H*-indazol-1-yl)phenyl]-*N*-methylacetamide (Intermediate 15, 206mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (167mg), tetrakis(triphenylphosphine)palladium (13.8mg) and aqueous sodium hydrogen carbonate (1M, 1.2ml) in isopropanol (2.8ml). The silica SPE cartridge was eluted with a chloroform/methanol gradient to give the title compound as a yellow oil (147mg).

LC-MS: Rt 3.10min, MH⁺ 457.

Example 29: 3-[1-(4-Bromophenyl)-1*H*-indazol-5-yl]-*N*-cyclopropyl-5-fluoro-4-methylbenzamide



***N*-Cyclopropyl-4',5-difluoro-3'-formyl-6-methyl-3-biphenylcarboxamide**


(Intermediate 16, 158mg) and 4-bromophenylhydrazine (94mg) were combined in acetonitrile (3.1ml) and the mixture was warmed until a precipitate formed. The acetonitrile was removed under vacuum, the residue was dissolved in DMSO (6.2ml) and cesium carbonate (210mg) was added. The mixture was heated at 150°C in a microwave oven for 10min. The reaction mixture was diluted with ethyl acetate (10ml), washed with hydrochloric acid (1M, 5ml), saturated sodium carbonate (5ml) and brine (5ml). The organic phase was dried (magnesium sulfate) and concentrated under vacuum. The residue was purified using an SPE cartridge (silica) eluting with a cyclohexane/ethyl acetate gradient to give the title compound as a pale yellow solid (135mg).

LC-MS: Rt 3.87min, MH⁺ 464, 466.

General Method 2


A mixture of 3-[1-(4-bromophenyl)-1*H*-indazol-5-yl]-*N*-cyclopropyl-5-fluoro-4-methylbenzamide (Example 29, 1eq), amine (1.2eq) and sodium tert-butoxide (4.5eq) was treated with a solution of tris(dibenzylideneacetone)dipalladium (0.015eq) and tri-*t*-butylphosphoniumtetrafluoroborate (0.3eq) in dry DME (10ml/eq) then heated at 125°C for 18h. The solvent was evaporated and the residue was partitioned between ethyl acetate and water. Isolation of the crude product from the organic layer was followed by purification on an acidic ion-exchange column (SCX) and/or preparative HPLC.

Example 30: 3-(1-{4-[(Cyclohexylmethyl)amino]phenyl}-1*H*-indazol-5-yl)-*N*-cyclopropyl-5-fluoro-4-methylbenzamide, formate salt



The title compound was prepared by General Method 2 using cyclohexylmethylamine (12mg) to give a brown oil (7mg).
LC-MS: Rt 4.16min, MH⁺ 497.


Example 31: *N*-Cyclopropyl-3-[1-(4-{2-(dimethylamino)ethyl}amino)phenyl]-1*H*-indazol-5-yl]-5-fluoro-4-methylbenzamide, diformate salt



The title compound was prepared by General Method 2 using N,N-dimethylethylenediamine (0.014ml) to give a white solid (20mg).

LC-MS: Rt 2.64min, MH⁺ 472.


5 **Example 32:** *N*-Cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(tetrahydro-2H-pyran-4-ylamino)phenyl]-1H-indazol-5-yl}benzamide, formate salt



10 The title compound was prepared by General Method 2 using tetrahydro-2H-pyran-4-ylamine (20mg) to give a brown solid (18mg).

LC-MS: Rt 3.40min, MH⁺ 485.


15 **Example 33:** *N*-Cyclopropyl-3-fluoro-4-methyl-5-(1-{4-[(tetrahydro-2-furanylmethyl)amino]phenyl}-1H-indazol-5-yl)benzamide, formate salt



20 The title compound was prepared by General Method 2 using (tetrahydro-2-furanylmethyl)amine (0.014ml) to give a brown glass (12mg).

LC-MS: Rt 3.56min, MH⁺ 485.


Example 34: *N*-Cyclopropyl-3-fluoro-4-methyl-5-[1-(4-{[2-(methyloxy)ethyl]amino}phenyl)-1H-indazol-5-yl]benzamide, formate salt



The title compound was prepared by General Method 2 using 2-methoxyethylamine (0.011ml) to give a brown glass (15mg).

5 LC-MS: Rt 3.40min, MH⁺ 459.


Example 35: N-Cyclopropyl-3-[1-(4-[3-(dimethylamino)propyl]amino)phenyl]-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide, diformate salt



The title compound was prepared by General Method 2 using N,N-dimethyl-1,3-propanediamine (0.016ml) to give a brown glass (10mg).

LC-MS: Rt 2.67min, MH⁺ 486.


Example 36: (±)-N-Cyclopropyl-3-(1-(4-[(2,3-dihydroxypropyl)amino]phenyl)-1H-indazol-5-yl)-5-fluoro-4-methylbenzamide



The title compound was prepared by General Method 2 using [(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]amine (0.025ml) to give an off-white solid (14.6mg).

5 LC-MS: Rt 3.03min, MH+ 475.

Example 37: N-Cyclopropyl-3-[1-(2,6-dimethyl-4-pyrimidinyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide



10


N-Cyclopropyl-4',5-difluoro-3'-formyl-6-methyl-3-biphenylcarboxamide (Intermediate 16, 37mg) and 4-hydrazino-2,6-dimethylpyrimidine (20mg,) were stirred together in acetonitrile (5ml) for 2h and then at 50°C for 42h. The solvent was evaporated and the residue was dissolved in DMSO (5ml). Cesium carbonate (41.5mg) was added and the mixture was heated at 180°C in a microwave oven for 20min. The solution was diluted with ethyl acetate (20ml) then extracted with hydrochloric acid (0.5M, 3x20ml). The combined acid fractions were basified to pH8 and extracted with chloroform (3x20ml). The chloroform extracts were reduced to dryness under vacuum and the residue was purified by preparative HPLC to give the title compound as a yellow glass (3.7g).

15

20

LC-MS: Rt 2.42min, MH+ 416.


Example 38: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(6-oxo-1,6-dihydro-4-pyrimidinyl)-1H-indazol-5-yl]benzamide



N-Cyclopropyl-4',5-difluoro-3'-formyl-6-methyl-3-biphenylcarboxamide (Intermediate 16, 40mg) and 6-hydrazino-4(1*H*)-pyrimidinone (24mg,) were mixed in acetonitrile (5ml) and stirred at 60°C for 18h. The solvent was evaporated and the residue was dissolved in DMSO (5ml). Cesium carbonate (49.5mg) was added and the mixture was heated at 180°C in a microwave oven for 15min. The reaction mixture was diluted with chloroform/ethyl acetate (1:1, 10ml), washed with water (2x10ml) and brine (1x10ml) then concentrated under vacuum to give the title compound as a yellow solid (32mg).

LC-MS: Rt 3.05min, MH⁺ 404.

Example 39: *N*-Cyclopropyl-3-fluoro-4-methyl-5-{3-[4-(methyloxy)phenyl]-1,2-benzisoxazol-6-yl}benzamide




A suspension of 6-bromo-3-[4-(methyloxy)phenyl]-1,2-benzisoxazole (30mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (28mg), tetrakis(triphenylphosphine)palladium(0) (1mg) and saturated aqueous sodium hydrogen carbonate (0.25ml) in isopropanol (1ml) was stirred at reflux under nitrogen for 6h. The isopropanol was removed under vacuum and the residue was partitioned between dichloromethane (3ml) and water (3ml). The organic layer was separated using a hydrophobic filter tube, the solvent was evaporated and the residue was purified on an SPE cartridge (silica, 1g) eluting with cyclohexane/ethyl acetate (100:0 to 80:20) to give the title compound as a crunchy yellow foam (26mg).

LC-MS: Rt 3.68min, MH+ 417.

Example 40: N-Cyclopropyl-3-fluoro-5-[3-(4-hydroxyphenyl)-1,2-benzisoxazol-6-yl]-4-methylbenzamide


5



The procedure for Example 39 was followed using 4-(6-bromo-1,2-benzisoxazol-3-yl)phenol (60mg), {5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}boronic acid (52mg), tetrakis(triphenylphosphine)palladium(0) (2mg) and saturated aqueous sodium hydrogen carbonate (0.5ml) in isopropanol (2ml). Elution of the SPE cartridge (silica, 2g) with dichloromethane/methanol (100:0 to 98:2) gave an impure white solid (67mg) which was recrystallised from isopropanol to give the title compound as a crystalline white solid (35mg).


LC-MS: Rt 3.52min, MH+ 403.

Example 41: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinylmethyl)-1H-indazol-5-yl]benzamide



The procedure for Example 4 was followed using N-cyclopropyl-3-fluoro-5-(1H-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 70mg), sodium hydride (60% dispersion in mineral oil, 22mg), 3-(bromomethyl)pyridine hydrobromide (63mg) and DMF (5ml) to give the title compound as a colourless glass (12mg).


LC-MS: Rt 2.80min, MH+ 401.

Example 42: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(4-pyridinylmethyl)-1H-indazol-5-yl]benzamide

5

The procedure for Example 4 was followed using *N*-cyclopropyl-3-fluoro-5-(1*H*-indazol-5-yl)-4-methylbenzamide (Intermediate 5, 70mg), sodium hydride (60% dispersion in mineral oil, 22mg), 4-(bromomethyl)pyridine hydrobromide (63mg) and DMF (5ml) to give the title compound as a colourless glass (11mg).

10 LC-MS: Rt 2.92min, MH⁺ 401.


Example 43: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-2-pyridinyl)methyl]-1H-indazol-5-yl]benzamide

15

A solution of *N*-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-pyridinylmethyl)-1*H*-indazol-5-yl]benzamide (Example 8, 7mg) in chloroform (1.6ml) was treated with *m*-CPBA (5.2mg) then stirred at 60°C for 1h. Methanol (5ml) was added and the solution was applied to an Isolute amino cartridge. Elution with methanol gave the title compound as a white solid (8mg).


20 LC-MS: Rt 2.77min, MH⁺ 417.

Example 44: N-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-3-pyridinyl)methyl]-1H-indazol-5-yl]benzamide



5 The procedure for Example 43 was followed using *N*-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinylmethyl)-1*H*-indazol-5-yl]benzamide (Example 41, 7mg) *m*-CPBA (5.2mg) and chloroform (3ml) to give the title compound as a white solid (7mg).
LC-MS: Rt 2.67min, MH⁺ 417.

Example 45: *N*-Cyclopropyl-3-fluoro-4-methyl-5-[1-[(1-oxido-4-pyridinyl)methyl]-1*H*-indazol-5-yl]benzamide




10 The procedure for Example 43 was followed using *N*-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-pyridinylmethyl)-1*H*-indazol-5-yl]benzamide (Example 42, 8mg) *m*-CPBA (5.9mg) and chloroform (2ml) to give the title compound as a white solid (8mg).
LC-MS: Rt 2.66min, MH⁺ 417.

15

General Method 3


20 A mixture of 3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzoic acid (Intermediate 9, 224mg) in thionyl chloride (7.5ml) was stirred at reflux for 3h. Excess thionyl chloride was removed under vacuum and the residue was azeotroped with toluene to remove residual thionyl chloride. The crude acid chloride (187mg) was dissolved in chloroform (10ml) and an aliquot (1.0ml) was added to a solution of the appropriate amine (100μmol) in a mixture (0.5ml) prepared by the addition of diisopropylethylamine (69μl), and dimethylaminopyridine (6mg) to DMF (20ml). The resulting mixture was left at room temperature for 16h, diisopropylethylamine (12μl) was added and the mixture was heated
25 at 50°C for 24h under nitrogen. The resulting gums were purified by preparative HPLC.

Example 46: 3-Fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)-*N*-2-pyrimidinylbenzamide




5 The title compound (1.3mg) was prepared by General Method 3 using 2-aminopyrimidine.
LC-MS: Rt 3.40min, MH⁺ 424.

Example 47: 3-Fluoro-*N*-(4-fluorophenyl)-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide



10 The title compound (4.1mg) was prepared by General Method 3 using 4-fluoroaniline.
LC-MS: Rt 4.0min, MH⁺ 440.


Example 48: 3-Fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)-*N*-3-pyridazinylbenzamide



The title compound (3.1mg) was prepared by General Method 3 using 2-aminopyridazine.

5 LC-MS: Rt 3.58min, MH+ 424.


Example 49: 3-Fluoro-4-methyl-5-(1-phenyl-1H-indazol-5-yl)-N-1H-pyrazol-3-ylbenzamide



10 The title compound (2.9mg) was prepared by General Method 3 using 3-aminopyrazole.

LC-MC: 4.10min, MH+ 412.


Example 50: N-(4-Fluorophenyl)-4-methyl-3-(1-phenyl-1H-indazol-5-yl)benzamide



A mixture of 5-bromo-1-phenyl-1*H*-indazole (Intermediate 1, 39mg), *N*-cyclobutyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 23, 50mg), tetrakis(triphenylphosphine)palladium (0) (3mg) and 2M aqueous sodium bicarbonate in isopropanol (1 ml) was heated at 150°C for 10min in a microwave oven. The reaction mixture was applied to an SPE cartridge (silica, 50g) and eluted with a cyclohexane/ethyl acetate gradient (100:0 to 0:100) to give the title compound as a white solid (40mg).

LC-MS: Rt 3.80min, MH⁺ 422.


Example 51: *N*-Ethyl-3-[3-(4-fluorophenyl)-1*H*-indazol-6-yl]-4-methylbenzamide



A mixture of 6-bromo-3-(4-fluorophenyl)-1*H*-indazole (Intermediate 20, 27mg), *N*-ethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 18, 29mg), tetrakis(triphenylphosphine)palladium(0) (2mg) and aqueous sodium hydrogen carbonate (1M, 1ml) in isopropanol (2ml) was stirred in a microwave oven at 150°C for 15min. Water and chloroform were added and the organic layer was separated using a hydrophobic filter tube. The solvent was evaporated and the residue was purified on an SPE cartridge (silica, 2g) eluting with cyclohexane/ethyl acetate (100:0 to 50:50) to give the title compound (21mg).

LC-MS: Rt 3.40min, MH⁺ 374.


Example 52: *N*-Cyclopropyl-3-[3-(4-fluorophenyl)-1*H*-indazol-6-yl]-4-methylbenzamide



The procedure for Example 51 was followed using 6-bromo-3-(4-fluorophenyl)-1*H*-indazole (Intermediate 20, 27mg), *N*-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (30mg), tetrakis(triphenylphosphine)palladium(0) (2mg) and aqueous sodium hydrogen carbonate (1M, 1ml) in isopropanol (2ml) to give the title compound (20mg).

LC-MS: Rt 3.3min, MH⁺ 386.


Example 53: *N*-Ethyl-4-methyl-3-{3-[4-(methyloxy)phenyl]-1*H*-indazol-6-yl}benzamide



The procedure for Example 51 was followed using 6-bromo-3-(4-methoxyphenyl)-1*H*-indazole (Intermediate 22, 23mg), *N*-ethyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Intermediate 18, 30mg), tetrakis(triphenylphosphine)palladium(0) (2mg) and aqueous sodium hydrogen carbonate (1M, 1ml) in isopropanol (2ml) to give the title compound (18mg).

LC-MS: Rt 3.41min, MH⁺ 386.

Example 54: *N*-Cyclopropyl-4-methyl-3-{3-[4-(methyloxy)phenyl]-1*H*-indazol-6-yl}benzamide



The procedure for Example 51 was followed using 6-bromo-3-(4-methoxyphenyl)-1*H*-indazole (Intermediate 22, 23mg), *N*-cyclopropyl-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (30mg), tetrakis(triphenylphosphine)palladium(0) (2mg) and aqueous sodium hydrogen carbonate (1M, 1ml) in isopropanol (2ml) to give the title compound (22mg).
LC-MS: Rt 3.32min, MH⁺ 397.

Abbreviations

10	AcOH	Acetic acid
	Boc	t-Butoxycarbonyl
	DBU	1,8-Diazabicyclo[5.4.0]undec-7-ene
	DIPEA	N,N-Diisopropylethylamine
	DME	1,2-Dimethoxyethane
15	DMF	Dimethylformamide
	DMSO	Dimethylsulfoxide
	EtOH	Ethanol
	h	Hours
	Hal	Halogen
20	HATU	O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
	m-CPBA	3-Chloroperbenzoic acid
	MeCN	Acetonitrile
	MeOH	Methanol
25	min	Minutes
	Ms	Mesyl
	PdCl ₂ (dppf)	[1,1'-bis(Diphenylphosphino)ferrocene]dichloropalladium (II) complex with dichloromethane (1:1)
	Rt	Retention Time
30	SPE	Solid phase extraction
	THF	Tetrahydrofuran

BIOLOGICAL EXAMPLES

The activity of compounds of formula (I) as p38 inhibitors may be determined by the following *in vitro* assays:

Fluorescence anisotropy kinase binding assay

The kinase enzyme, fluorescent ligand and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) enzyme bound and in the presence of a sufficient concentration (>10x K_i) of a potent

inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value.

The concentration of kinase enzyme should preferably be $\geq 1 \times K_i$. The concentration of fluorescent ligand required will depend on the instrumentation used, and the fluorescent and physicochemical properties. The concentration used must be lower than the concentration of kinase enzyme, and preferably less than half the kinase enzyme concentration. A typical protocol is:

All components dissolved in Buffer of final composition 62.5 mM HEPES, pH 7.5, 1.25 mM CHAPS, 1.25 mM DTT, 12.5 mM $MgCl_2$ 3.3% DMSO.

p38 Enzyme concentration: 12 nM

Fluorescent ligand concentration: 5 nM

Test compound concentration: 0.1 nM - 100 μ M


Components incubated in 30 μ l final volume in NUNC 384 well black microtitre plate until equilibrium reached (5-30 mins)

Fluorescence anisotropy read in LJJL Acquest.

Definitions: K_i = dissociation constant for inhibitor binding

K_f = dissociation constant for fluorescent ligand binding

The fluorescent ligand is the following compound:



which is derived from 5-[2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol and rhodamine green.


Results

The compounds described in the Examples were tested as described above and had IC_{50} values of $<10 \mu$ M.

CLAIMS

1. A compound of formula (I):

5



(I)

wherein

10 A is a fused 5-membered heteroaryl ring substituted by $-(CH_2)_m$ aryl or $-(CH_2)_m$ heteroaryl wherein the aryl or heteroaryl is optionally substituted by one or more substituents independently selected from oxo, C₁₋₆alkyl, halogen, -CN, trifluoromethyl, -OR³, $-(CH_2)_nCO_2R^3$, -NR³R⁴, $-(CH_2)_nCONR^3R^4$, -NHCOR³, -SO₂NR³R⁴, -NHSO₂R³ and -S(O)_pR³, and

15 A is optionally further substituted by one substituent selected from -OR⁵, halogen, trifluoromethyl, -CN, -CO₂R⁵ and C₁₋₆alkyl optionally substituted by hydroxy;

R¹ is selected from methyl and chloro;

R² is selected from -NH-CO-R⁶ and -CO-NH-(CH₂)_q-R⁷;

20 R³ is selected from hydrogen, $-(CH_2)_r$ C₃₋₇cycloalkyl, $-(CH_2)_r$ heterocyclyl, $-(CH_2)_r$ aryl, and C₁₋₆alkyl optionally substituted by up to two substituents independently selected from -OR⁸ and -NR⁸R⁹,

R⁴ is selected from hydrogen and C₁₋₆alkyl, or

R³ and R⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

25 R⁵ is selected from hydrogen and C₁₋₆alkyl;

R⁶ is selected from hydrogen, C₁₋₆alkyl, $-(CH_2)_q$ C₃₋₇cycloalkyl, trifluoromethyl, $-(CH_2)_s$ heteroaryl optionally substituted by R¹¹ and/or R¹², and $-(CH_2)_s$ phenyl optionally substituted by R¹¹ and/or R¹²;

30 R⁷ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, -CONHR¹³, phenyl optionally substituted by R¹¹ and/or R¹², and heteroaryl optionally substituted by R¹¹ and/or R¹²;

R⁸ and R⁹ are each independently selected from hydrogen and C₁₋₆alkyl;

R¹⁰ is selected from hydrogen and methyl;

R¹¹ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_q-C₃₋₇cycloalkyl, -CONR¹³R¹⁴, -NHCOR¹⁴, halogen, -CN, -(CH₂)_tNR¹⁵R¹⁶, trifluoromethyl, phenyl optionally substituted by one or more R¹² groups, and heteroaryl optionally substituted by one or more R¹² groups;

5 R¹² is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl, and -(CH₂)_tNR¹⁵R¹⁶;

R¹³ and R¹⁴ are each independently selected from hydrogen and C₁₋₆alkyl, or

10 R¹³ and R¹⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰, wherein the ring may be substituted by up to two C₁₋₆alkyl groups;

R¹⁵ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)_q-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl,

R¹⁶ is selected from hydrogen and C₁₋₆alkyl, or

15 R¹⁵ and R¹⁶, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

X and Y are each independently selected from hydrogen, methyl and halogen;

m, n, p and q are each independently selected from 0, 1 and 2;

20 r and s are each independently selected from 0 and 1; and

t is selected from 0, 1, 2 and 3;

with the proviso that when A is substituted by -(CH₂)_mheteroaryl and m is 0, the -(CH₂)_mheteroaryl group is not a 5-membered heteroaryl ring optionally substituted by C₁₋₂alkyl;

25 or a pharmaceutically acceptable derivative thereof.

2. A compound according to claim 1 wherein A is a fused 5-membered heteroaryl ring containing up to two heteroatoms independently selected from oxygen and nitrogen.

30 3. A compound according to claim 1 or claim 2 wherein R¹ is methyl.

4. A compound according to any one of the preceding claims wherein R² is -CO-NH-(CH₂)_q-R⁷.


35 5. A compound according to any one of the preceding claims wherein A is substituted by -(CH₂)_mheteroaryl wherein the heteroaryl is a 5- or 6-membered heteroaryl ring containing up to two heteroatoms independently selected from oxygen and nitrogen.

40 6. A compound according to claim 5 wherein the heteroaryl is substituted by one or two substituents independently selected from oxo and C₁₋₆alkyl.

7. A compound according to any one of claims 1 to 4 wherein A is substituted by $-(CH_2)_m$ aryl wherein the aryl is phenyl.
8. A compound according to claim 7 wherein the aryl is substituted by one or two substituents independently selected from C_{1-6} alkyl, in particular methyl, halogen, $-CN$, trifluoromethyl, $-OR^3$, $-NR^3R^4$, $-(CH_2)_nCONR^3R^4$ and $-S(O)_pR^3$.
9. A compound according to any one of the preceding claims wherein X is hydrogen or fluorine.
10. A compound according to claim 1 substantially as hereinbefore defined with reference to any one of Examples 1 to 54, or a pharmaceutically acceptable derivative thereof.
11. A compound according to claim 1 selected from:
N-cyclopropyl-3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide;
N-cyclopropyl-3-fluoro-5-[1-(4-fluorophenyl)-1*H*-indazol-5-yl]-4-methylbenzamide;
N-cyclopropyl-3-fluoro-5-[1-(4-fluoro-2-methylphenyl)-1*H*-indazol-5-yl]-4-methylbenzamide;
N-cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(4-morpholinyl)phenyl]-1*H*-indazol-5-yl}benzamide;
N-ethyl-3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide;
N-(cyclopropylmethyl)-3-fluoro-4-methyl-5-(1-phenyl-1*H*-indazol-5-yl)benzamide;
N-cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(methylsulfonyl)phenyl]-1*H*-indazol-5-yl}benzamide;
N-cyclopropyl-3-fluoro-4-methyl-5-(1-{4-[2-(methylamino)-2-oxoethyl]phenyl}-1*H*-indazol-5-yl)benzamide;
N-cyclopropyl-3-[1-(4-{[2-(dimethylamino)ethyl]amino}phenyl)-1*H*-indazol-5-yl]-5-fluoro-4-methylbenzamide;
N-cyclopropyl-3-fluoro-4-methyl-5-{1-[4-(tetrahydro-2*H*-pyran-4-ylamino)phenyl]-1*H*-indazol-5-yl}benzamide;
N-cyclopropyl-3-fluoro-4-methyl-5-(1-{4-[(tetrahydro-2-furanylmethyl)amino]phenyl}-1*H*-indazol-5-yl)benzamide;
N-cyclopropyl-3-(1-{4-[(2,3-dihydroxypropyl)amino]phenyl}-1*H*-indazol-5-yl)-5-fluoro-4-methylbenzamide;
N-cyclopropyl-3-fluoro-4-methyl-5-{3-[4-(methyloxy)phenyl]-1,2-benzisoxazol-6-yl}benzamide;
N-cyclopropyl-3-fluoro-5-[3-(4-hydroxyphenyl)-1,2-benzisoxazol-6-yl]-4-methylbenzamide;
N-cyclopropyl-3-fluoro-4-methyl-5-{1-[(1-oxido-2-pyridinyl)methyl]-1*H*-indazol-5-yl}benzamide;
N-ethyl-3-[3-(4-fluorophenyl)-1*H*-indazol-6-yl]-4-methylbenzamide;
N-cyclopropyl-3-[3-(4-fluorophenyl)-1*H*-indazol-6-yl]-4-methylbenzamide;


N-ethyl-4-methyl-3-{3-[4-(methyloxy)phenyl]-1*H*-indazol-6-yl}benzamide; and
N-cyclopropyl-4-methyl-3-{3-[4-(methyloxy)phenyl]-1*H*-indazol-6-yl}benzamide; or
 a pharmaceutically acceptable derivative thereof.

- 5 12. A pharmaceutical composition comprising at least one compound as claimed in any one of claims 1 to 11, or a pharmaceutically acceptable derivative thereof, in association with one or more pharmaceutically acceptable excipients, diluents and/or carriers.
- 10 13. A compound according to any one of claims 1 to 11, or a pharmaceutically acceptable derivative thereof, for use in therapy.
- 15 14. A method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase comprising administering to a patient in need thereof a compound as claimed in any one of claims 1 to 11, or a pharmaceutically acceptable derivative thereof.
- 20 15. Use of a compound as claimed in any one of claims 1 to 11, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for use in the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.
- 25 16. A process for preparing a compound of formula (I) as claimed in any one of claims 1 to 11, or a pharmaceutically acceptable derivative thereof, which comprises
- (a) reacting a compound of formula (II)




(II)

- 30 in which R¹, R², X and Y are as defined in claim 1 and A¹ is an unsubstituted fused 5-membered heteroaryl ring with a halide derivative of formula (IIIA) or (IIIB)




(IIIA)



(IIIB)

- 5 in which $-(\text{CH}_2)_m\text{aryl}$ and $-(\text{CH}_2)_m\text{heteroaryl}$ are as defined in claim 1 and Z is halogen, in the presence of a base,
or, when A is substituted by $-(\text{CH}_2)_m\text{aryl}$ wherein m is 0, reacting the compound of formula (II) with a boronic acid compound of formula (IV)


10



(IV)

in which $-(\text{CH}_2)_m\text{aryl}$ is as defined in claim 1,


- (b) reacting a compound of formula (V)



15


(V)

in which A^2 is A as defined in claim 1 and Z^1 is halogen, with a compound of formula (VIA) or (VIB)



20

(VIA)




73

(VIB)


in which R^1 , R^2 , X and Y are as defined in claim 1,
in the presence of a catalyst;

- 5 (c) reacting a compound of formula (XVI)



(XVI)


- 10 in which A, R^1 , X and Y are as defined in claim 1,
with an amine compound of formula (XV)



(XV)

- 15 in which R^7 and q are as defined in claim 1,
under amide forming conditions;


- d) when A is a fused pyrazolyl, reacting a compound of formula (XVII)



20


in which R^1 , R^2 , X and Y are as defined in claim 1 and Z^3 is halogen,
with a hydrazine derivative of formula (VIII A) or (VIII B)

(XVII)



25

(VIII A)



(VIII B)

in which $-(\text{CH}_2)_m\text{aryl}$ and $-(\text{CH}_2)_m\text{heteroaryl}$ are as defined in claim 1; or

5

(e) final stage modification of one compound of formula (I) as defined in claim 1 to give another compound of formula (I) as defined in claim 1.

10

